NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia (NCT05693558) | Clinical Trial Compass
UnknownPhase 1
NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia
United States, Belgium4 participantsStarted 2022-11-24
Plain-language summary
A single arm, multi-country, multi-center study in pediatric patients, suffering from congenital pseudarthrosis of the tibia (CPT), treated during the primary surgical intervention with NVD-003, an autologous 3D scaffold free osteogenic graft.
Who can participate
Age range2 Years – 8 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed with congenital pseudarthrosis of the tibia (with or without NF1) and presenting with a non-healing Paley type 3 or 4 fracture.
* Minimum weight of 5kg/11lbs.
* Maximum 2 previous failed surgical orthopaedic interventions to treat the primary CPT fracture.
* Acceptable serology and molecular test results excluding the presence of viruses
* Satisfactory general health condition to undergo surgeries (ATC and GS) with anaesthesia as per local standards.
* The patient's parent(s) and/or legal guardian(s) provided written informed consent and accepted the participation of the patient in the trial.
Exclusion Criteria:
* Bilateral CPT.
* Presence of CPT without a fracture of the tibia (Paley type 1 and 2).
* More than 2 failed surgical attempt(s) to treat the primary tibial fracture.
* Evidence of plexiform neurofibroma of any size or nodular fibroma ≥ 1.2in/3cm on the ipsilateral leg.
* Clinically significant infection at the target grafting site or systemic infection.
* Presence of clinically significant hematologic, renal, hepatic, and coagulation laboratory abnormalities (i.e., CBC, PT/INR, Chem-7, and LFTs, etc.).
* Presence of any auto-immune disease, with exception of well controlled diabetes type 1 or auto-immune thyroid disorders.
* Any history of experimental therapy with another investigational drug within 60 days prior to screening.
* Presence of active tumour.
* Documented metabolic bone disease or any disorder, such as but not limited…
What they're measuring
1
Primary objective: safety short (≤3 months) and mid long-term (>3-12 months): : Descriptive analysis